The Effect of Dapagliflozin on Patients With Cardiomyopathy

Launched by MAY MOHAMED ABDALLA · Jul 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether starting a medicine called dapagliflozin early during a hospital stay can help adults who are experiencing acute heart failure, a sudden worsening of their heart condition. The researchers want to see if dapagliflozin, when added to standard treatment with water pills (diuretics), can reduce fluid buildup in the lungs, shorten the time spent in the hospital, and improve heart and kidney health. About 140 patients will be randomly assigned to receive either dapagliflozin plus diuretics or diuretics alone, and the team will use lung ultrasounds and blood tests to measure the effects.

Adults 18 years or older who are hospitalized with acute heart failure and have signs of fluid overload may be eligible. This includes people with different types of heart failure, as long as they are planned to receive intravenous diuretics. Some conditions, like type 1 diabetes, low blood pressure, serious kidney or liver problems, or pregnancy, would exclude someone from joining. Participants can expect to have lung ultrasounds and blood tests during their hospital stay to track how well the treatment works, and the study is taking place at Kasr Al Ainy Hospital in Cairo. The goal is to find better ways to manage heart failure and improve recovery for patients like you or your loved ones.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years or older
• • Acute heart failure as defined by the 2022 American College of Cardiology/American Heart Association (Heidenreich et al., 2022) or 2021 European Society of Cardiology (McDonagh et al., 2021) guidelines, based on typical symptoms and signs of heart failure requiring hospitalization or emergency department visit
• • Elevated natriuretic peptide levels
• • Includes heart failure with reduced, mildly reduced, or preserved ejection fraction
• • Planned use of intravenous diuretic therapy
• Exclusion Criteria:
• • Type 1 diabetes mellitus
• • Urinary tract or genital infection
• • Hypovolemia
• • Diabetic ketoacidosis
• • Serum glucose \< 80 mg/dL at enrollment
• • Systolic blood pressure \< 90 mmHg at enrollment
• • History of hypersensitivity to any SGLT2 inhibitor
• • Pregnant or breastfeeding women
• • Severe primary valvular lesion requiring intervention
• • Severe hepatic impairment (Child-Pugh class C)
• • Estimated glomerular filtration rate \< 25 mL/min/1.73 m² (by MDRD equation)